Drug intelligence / Profile preview

somatropin + human pituitary follicle-stimulating hormone + GnRH antagonist

Development stage: Unknown
Lead developer: Riyadh Fertility and Reproductive Health Center
Modality: Peptides
Administration: Subcutaneous, Intramuscular

Overview

This combination regimen is an adjunctive therapy investigated for women with poor ovarian response undergoing in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI). It consists of somatropin (recombinant human growth hormone), human pituitary follicle-stimulating hormone (FSH), and a GnRH antagonist. Somatropin acts as an agonist at the growth hormone receptor, enhancing ovarian sensitivity to FSH and promoting follicular maturation by increasing the production of insulin-like growth factor-1 (IGF-1). FSH binds to the follicle-stimulating hormone receptor to drive follicular development and estrogen production. The GnRH antagonist binds to the gonadotropin-releasing hormone receptor to suppress premature luteinizing hormone (LH) surges, thereby preventing untimely ovulation during controlled ovarian hyperstimulation. This multi-drug protocol is primarily studied by the Riyadh Fertility and Reproductive Health Center.

Other names: growth hormone + human pituitary follicle-stimulating hormone + GnRH antagonistGH + FSH + GnRH antagonist

Targets

FSHR (Follicle-stimulating hormone receptor)GnRHR (Gonadotropin-releasing hormone receptor)GHR (Growth hormone receptor)

Beyond the preview

Go deeper on somatropin + human pituitary follicle-stimulating hormone + GnRH antagonist.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on somatropin + human pituitary follicle-stimulating hormone + GnRH antagonist.

Explore the full profile